245 related articles for article (PubMed ID: 35040284)
1. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
Tatineni S; Tarockoff M; Abdallah N; Purrington KS; Assad H; Reagle R; Petrucelli N; Simon MS
Cancer Med; 2022 Mar; 11(6):1465-1473. PubMed ID: 35040284
[TBL] [Abstract][Full Text] [Related]
2. Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center.
Abdallah N; Purrington KS; Tatineni S; Assad H; Petrucelli N; Simon MS
Cancer Causes Control; 2023 Feb; 34(2):141-149. PubMed ID: 36370215
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
4. Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer.
Yadav S; LaDuca H; Polley EC; Hu C; Niguidula N; Shimelis H; Lilyquist J; Na J; Lee KY; Gutierrez S; Yussuf A; Hart SN; Davis BT; Chao EC; Pesaran T; Goldgar DE; Dolinsky JS; Couch FJ
J Natl Cancer Inst; 2021 Oct; 113(10):1429-1433. PubMed ID: 33146377
[TBL] [Abstract][Full Text] [Related]
5. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract][Full Text] [Related]
6. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
7. Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer.
Seagle HM; Keller SR; Tavtigian SV; Horton C; Holowatyj AN
J Clin Oncol; 2023 Sep; 41(26):4279-4289. PubMed ID: 37319387
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer.
Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
[TBL] [Abstract][Full Text] [Related]
9. Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
Chapman-Davis E; Zhou ZN; Fields JC; Frey MK; Jordan B; Sapra KJ; Chatterjee-Paer S; Carlson AD; Holcomb KM
J Gen Intern Med; 2021 Jan; 36(1):35-42. PubMed ID: 32720237
[TBL] [Abstract][Full Text] [Related]
10. Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants.
Liu YL; Maio A; Kemel Y; Salo-Mullen EE; Sheehan M; Tejada PR; Trottier M; Arnold AG; Fleischut MH; Latham A; Carlo MI; Murciano-Goroff YR; Walsh MF; Mandelker D; Mehta N; Bandlamudi C; Arora K; Zehir A; Berger MF; Solit DB; Aghajanian C; Diaz LA; Robson ME; Brown CL; Offit K; Hamilton JG; Stadler ZK
Cancer; 2022 Nov; 128(21):3870-3879. PubMed ID: 36041233
[TBL] [Abstract][Full Text] [Related]
11. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
[TBL] [Abstract][Full Text] [Related]
12. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
13. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.
Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H
Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423
[TBL] [Abstract][Full Text] [Related]
14. Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing.
Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Holth A; Capella G; Davidson B; Evans DG; Martins A; Møller P; Hovig E
Sci Rep; 2019 Dec; 9(1):18555. PubMed ID: 31811167
[TBL] [Abstract][Full Text] [Related]
15. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
16. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
[TBL] [Abstract][Full Text] [Related]
17. Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.
Jones T; Trivedi MS; Jiang X; Silverman T; Underhill M; Chung WK; Kukafka R; Crew KD
J Cancer Educ; 2021 Jun; 36(3):463-469. PubMed ID: 31802423
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study.
Adam F; Fluri M; Scherz A; Rabaglio M
BMC Med Genomics; 2023 Jan; 16(1):7. PubMed ID: 36647026
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
van Marcke C; Collard A; Vikkula M; Duhoux FP
Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
[TBL] [Abstract][Full Text] [Related]
20. Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
Cox DM; Nelson KL; Clytone M; Collins DL
Mol Genet Genomic Med; 2018 Nov; 6(6):1236-1242. PubMed ID: 30152102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
